GIP and GLP-1 receptor co-agonist
CT-388 7.5 mg injection
CT388_SC_7p5MG_OTHER
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.74 (0.24 to 116) | 0.22 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 21.28 (3.32 to 182) | 0.08 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.61 (1.43 to 105) | 0.24 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 6.83 (0.95 to 56.44) | 0.16 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.21 (0.00 to 4.28) | 0.87 |